NCT06009926 2026-03-18
Evaluation of Broccoli Seed and Sprout Extract for Detoxification of Carcinogens in Firefighters
National Cancer Institute (NCI)
Phase 2 Active not recruiting
Clinical Trials
32 trialsNCT06126276 2026-03-18
Testing the Use of Neratinib or the Combination of Neratinib and Palbociclib Targeted Treatment for HER2+ Solid Tumors (A ComboMATCH Treatment Trial)
National Cancer Institute (NCI)
Phase 2 Recruiting
NCT06136897 2026-03-18
Testing Trastuzumab and Pertuzumab in Patients With Higher Than Normal Copies of the HER2 Gene Found in Their Tumors (MATCH - Subprotocol J)
National Cancer Institute (NCI)
Phase 2 Active not recruiting
NCT06351371 2026-03-18
Testing JNJ-42756493 (Erdafitinib) as Potentially Targeting Treatment in Cancers With FGFR Mutations or Fusions (MATCH - Subprotocol K2)
National Cancer Institute (NCI)
Phase 2 Active not recruiting
NCT06360588 2026-03-17
Testing Copanlisib as Potentially Targeting Treatment in Cancers With PTEN Loss (MATCH - Subprotocol Z1G)
National Cancer Institute (NCI)
Phase 2 Active not recruiting
NCT06654050 2026-03-17
Alrizomadlin (APG-115) in Subjects With BAP1 Cancer Syndrome and Early-Stage Mesothelioma
National Institutes of Health Clinical Center (CC)
Phase 2 Withdrawn
NCT05960773 2026-03-04
Decitabine/Cedazuridine (INQOVI), an Oral DNA Demethylating Agent, in Subjects With BAP1 Cancer Predisposition Syndrome and Subclinical, Early-Stage Mesothelioma
National Institutes of Health Clinical Center (CC)
Phase 2 Suspended
NCT05715281 2025-11-25
Testing the Combination of Anti-cancer Drugs Atezolizumab and Tiragolumab in People With Advanced Stage Rare Cancers, RARE3 Trial
National Cancer Institute (NCI)
Phase 2 Active not recruiting
NCT06503146 2025-11-12
18F-Fibroblast Activation Protein Inhibitor ([18F]FAPI-74) PET Imaging for Cancer Detection
National Institutes of Health Clinical Center (CC)
Phase 2 Recruiting
NCT03253679 2023-10-17
AZD1775 in Treating Patients With Advanced Refractory Solid Tumors With CCNE1 Amplification
National Cancer Institute (NCI)
Phase 2 Completed
NCT01827384 2023-09-29
MPACT Study to Compare Effects of Targeted Drugs on Tumor Gene Variations
National Cancer Institute (NCI)
Phase 2 Completed
NCT03644550 2021-12-02
Anti-Mesothelin Immunotoxin LMB-100 Followed by Pembrolizumab in Malignant Mesothelioma
National Institutes of Health Clinical Center (CC)
Phase 2 Terminated
NCT03531840 2021-04-09
Olaparib in People With Malignant Mesothelioma
National Institutes of Health Clinical Center (CC)
Phase 2 Completed
NCT01624090 2019-12-30
Mithramycin for Lung, Esophagus, and Other Chest Cancers
National Institutes of Health Clinical Center (CC)
Phase 2 Terminated
NCT00365053 2018-06-07
PXD101 as Second-Line Therapy in Treating Patients With Malignant Mesothelioma of the Chest That Cannot Be Removed By Surgery
National Cancer Institute (NCI)
Phase 2 Completed
NCT01160458 2018-04-10
Phase II Study of IMC-A12 in Patients With Mesothelioma Who Have Been Previously Treated With Chemotherapy
National Institutes of Health Clinical Center (CC)
Phase 2 Completed
NCT01861301 2016-10-24
Tivantinib in Treating Patients With Previously Treated Malignant Mesothelioma
National Cancer Institute (NCI)
Phase 2 Terminated
NCT00004547 2015-11-18
Treatment of Peritoneal Cancer With Surgery, Perfused Heated Cisplatin and Chemotherapy
National Institutes of Health Clinical Center (CC)
Phase 2 Completed
NCT00831844 2015-03-30
Cixutumumab in Treating Patients With Relapsed or Refractory Solid Tumors
National Cancer Institute (NCI)
Phase 2 Completed
NCT00459862 2015-02-24
Pazopanib in Treating Patients With Malignant Pleural Mesothelioma
National Cancer Institute (NCI)
Phase 2 Completed
NCT00392444 2014-05-21
Sunitinib in Treating Patients With Advanced Malignant Pleural Mesothelioma
National Cancer Institute (NCI)
Phase 2 Completed
NCT00027703 2014-02-11
Combination Chemotherapy With or Without Bevacizumab in Treating Patients With Malignant Mesothelioma
National Cancer Institute (NCI)
Phase 2 Completed
NCT00024271 2014-01-06
Surgery, Chemotherapy, and Radiation Therapy in Treating Patients With Peritoneal Cancer
National Cancer Institute (NCI)
Phase 2 Unknown
NCT00030459 2013-08-07
Palliative Therapy With or Without Chemotherapy in Treating Patients With Malignant Mesothelioma
National Cancer Institute (NCI)
Phase 2 Unknown
NCT01105390 2013-08-02
AMG 102, Pemetrexed Disodium, and Cisplatin in Treating Patients With Malignant Pleural Mesothelioma
National Cancer Institute (NCI)
Phase 2 Withdrawn
NCT00002475 2013-07-10
Cyclophosphamide Plus Vaccine Therapy in Treating Patients With Advanced Cancer
National Cancer Institute (NCI)
Phase 2 Completed
NCT00062283 2013-06-26
Alanosine in Treating Patients With Cancer
National Cancer Institute (NCI)
Phase 2 Completed
NCT00107432 2013-06-05
Sorafenib Tosylate in Treating Patients With Malignant Mesothelioma.
National Cancer Institute (NCI)
Phase 2 Completed
NCT00006014 2013-06-03
SU5416 in Treating Patients With Malignant Mesothelioma
National Cancer Institute (NCI)
Phase 2 Completed
NCT00006102 2013-02-05
Rebeccamycin Analogue in Treating Children With Solid Tumors or Non-Hodgkin's Lymphoma
National Cancer Institute (NCI)
Phase 2 Completed
NCT00039182 2013-01-24
Erlotinib in Treating Patients With Malignant Mesothelioma of the Lung
National Cancer Institute (NCI)
Phase 2 Completed
NCT00541073 2011-05-17
Pemetrexed, Cisplatin, and Vitamin B12 in Treating Patients With Mesothelioma of the Chest That Cannot Be Removed by Surgery
National Cancer Institute (NCI)
Phase 2 Completed